← Back to Search
Tumor-specific Antibody-mediated Targeted Delivery Of Doxil Reduces The Manifestation Of Auricular Erythema Side Effect In Mice.
T. Elbayoumi, V. Torchilin
Published 2008 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
A mucocutaneous reaction in mice associated with Doxil treatment was identified as auricular erythema (AE). Given that the immuno-targeting of Doxil to tumors was found to influence also its systemic biodistribution pattern, the attempt was made to exploit a specific targeting of Doxil to reduce the manifestation of this adverse reaction. This problem is of general significance, since cutaneous reactions often lead to alterations of Doxil dosing regimen in patients and might subsequently compromise the therapeutic outcome of cancer treatment. Tumor-bearing mice were used to study the biodistribution and skin-tissue accumulation effects of the tumor-targeted Doxil (the clinically used anti-cancer formulation) coupled with the anti-cancer monoclonal 2C5 antibody (mAb 2C5) as well as AE caused by Doxil application. The modification of Doxil with mAb 2C5 resulted in a significant decrease in the normal skin accumulation of doxorubicin compared to original Doxil and substantially reduced AE. The frequency of AE was decreased by three to fourfold with the mAb 2C5-modified doxorubicin-loaded long-circulating liposomes. Thus, targeting of Doxil with the anti-cancer mAb 2C5 not only can increase the tumor-specific accumulation of the drug, but also diminishes the cutaneous side effect of the original Doxil therapy.
This paper references
Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo
B. Gupta (2005)
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
M. Lotem (2000)
p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups.
V. Torchilin (2001)
The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.
M. Hensley (2001)
Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity.
G. Charrois (2003)
Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
T. Elbayoumi (2007)
Exploiting the enhanced permeability and retention effect for tumor targeting.
A. Iyer (2006)
How to read a paper: Statistics for the non-statistician. II: “Significant” relations and their pitfalls
T. Greenhalgh (1997)
Enhanced Intracellular Uptake of Sterically Stabilized Liposomal Doxorubicin in Vitro Resulting in Improved Antitumor Activity in Vivo
X. Xiong (2005)
Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells.
T. Ishida (2001)
Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies
T. Elbayoumi (2006)
Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells.
L. Iakoubov (1995)
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis
G. Batist (2006)
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
G. Charrois (2004)
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
A. Klibanov (1990)
Pharmacokinetics of stealth versus conventional liposomes: effect of dose.
T. Allen (1991)
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
B. Uziely (1995)
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
M. Ranson (1997)
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
A. Hamilton (2002)
Antinucleosome Antibody-Modified Liposomes and Lipid-Core Micelles for Tumor-Targeted Delivery of Therapeutic and Diagnostic Agents
T. Elbayoumi (2007)
Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates
T. Allen (2005)
Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo.
T. Allen (1991)
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
T. Safra (2000)
The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin.
G. Berry (1998)
A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice.
Iakoubov Lz (1997)
Development of ligand-targeted liposomes for cancer therapy
C. Noble (2004)
Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.
A. Gordon (2000)
Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
F. Pastorino (2003)
Future directions of liposome- and immunoliposome-based cancer therapeutics.
J. Park (2004)
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
D. Papahadjopoulos (1991)
A single monoclonal antinuclear autoantibody with nucleosome-restricted specificity inhibits growth of diverse human tumors in nude mice
A. Chakilam (2004)
Sequential Combination of Paclitaxel-Carboplatin and Paclitaxel-Liposomal Doxorubicin as a First-Line Treatment in Patients with Ovarian Cancer
A. Potamianou (2005)
Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.
A. Lukyanov (2004)
Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity
G. Charrois (2003)
This paper is referenced by
Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin.
Jong Oh Kim (2009)
Experimental immunology Effect of doxorubicine on the immunological system in mice
J. Drozd (2010)
Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody
T. Elbayoumi (2009)
Antibody-targeted biodegradable nanoparticles for cancer therapy.
Vahid Heravi Shargh (2016)
A nanoliposome-based drug delivery system for cancer
J. Lin (2013)
Reversal of the multidrug resistance by drug combination using multifunctional liposomes
N. Patel (2013)
Immunoconjugates and long circulating systems: origins, current state of the art and future directions.
Alexander Koshkaryev (2013)
Barriers to drug delivery in solid tumors
Shravan Kumar Sriraman (2014)
Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells
X. Wu (2018)
Development of polymer and lipid based nano-delivery systems for targeted cancer chemotherapy
Mostafa Shahin (2012)
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.
A. Puri (2009)
The synergy between structural stability and DNA-binding controls the antibody production in EPC/DOTAP/DOPE liposomes and DOTAP/DOPE lipoplexes.
L. G. de la Torre (2009)
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.
Christopher D Spicer (2018)
Xiangji Chen (2012)
Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids.
Chiranjeevi Peetla (2010)
Nanocarriers for Diagnosis and Targeting of Breast Cancer
A. Sharma (2013)
The Use of Immunomicelles to Treat Ovarian Cancer
David R. Khan (2019)
What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future
Truffi Marta (2016)
Novel fluorescence molecular imaging of chemotherapy-induced intestinal apoptosis.
G. Levin (2009)
Improvement of drug safety by the use of lipid-based nanocarriers.
S. B. Lim (2012)
On the Use of Amperometry for Real Time Assessment of Drug‐Release Profile from Therapeutic Nanoparticles
A. A. Ensafi (2014)
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.
F. Perche (2012)
İnsan kordomalarında ekspresyon farkı olan MikroRNA'ların ve ilgili transkriptlerin incelenmesi ve bunların kordomaların patogenezindeki öneminin belirlenmesi
Ömer Bayrak (2010)
The Treatment of Breast Cancer Using Liposome Technology
S. Brown (2012)
Biodegradowalne jedwabne bionanokompozyty (SBC) do terapii celowanej i diagnostyki nowotworów
Florczak Anna (2013)
Passive and active drug targeting: drug delivery to tumors as an example.
V. Torchilin (2010)
Polymeric Nanoparticulates as Efficient Anticancer Drugs Delivery Systems
Shima Asfia (2019)
Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances
A. Shreya (2018)
Antibody-targeted nanoparticles for cancer therapy.
F. Fay (2011)
Antibody-modified liposomes for cancer chemotherapy
V. Torchilin (2008)
Advantages and risks of nanotechnologies in cancer patients and occupationally exposed workers
M. Lamberti (2014)
Controlled release application of multilamellar vesicles: a novel drug delivery approach
S. Agnihotri (2010)See more